Finding Acetylated-Lysine Sites in the Cancer Proteome

Information

  • Research Project
  • 7274036
  • ApplicationId
    7274036
  • Core Project Number
    R43CA128207
  • Full Project Number
    1R43CA128207-01
  • Serial Number
    128207
  • FOA Number
    RFA-CA-07-06
  • Sub Project Id
  • Project Start Date
    8/1/2007 - 17 years ago
  • Project End Date
    7/31/2008 - 16 years ago
  • Program Officer Name
    HEATH, ANNE K
  • Budget Start Date
    8/1/2007 - 17 years ago
  • Budget End Date
    7/31/2008 - 16 years ago
  • Fiscal Year
    2007
  • Support Year
    1
  • Suffix
  • Award Notice Date
    7/23/2007 - 17 years ago

Finding Acetylated-Lysine Sites in the Cancer Proteome

[unreadable] DESCRIPTION (provided by applicant): Recent studies indicate acetylated-lysine is an under-appreciated post-translational modification with a potentially prominent role in cancer biology. However, despite advances in proteomics, it is still difficult to find lysine acetylation sites in proteins. Although IMAC can be used to isolate phosphorylated peptides in bulk, there is no bulk purification technology for acetylated peptides. The long-term goal of this project is to develop and commercialize a proteomic method for isolating, identifying, and quantifying lysine acetylation sites. This method will contribute to the development of drugs that affect protein acetylation levels in cancer by elucidating their mechanisms of action. It will also identify new acetylation sites that could become targets for cancer diagnosis and treatment. During Phase I we will establish the method and its tools, using an immunoaffinity approach with an antibody specific for acetylated-lysine. We will first screen several acetylated-lysine monoclonal antibodies to select the one that performs best as an immunoprecipitation reagent and that best recognizes acetylated-lysine peptides in a sequence-independent manner. After choosing one antibody for further study, we will isolate and identify acetylated-lysine peptides from several cancer cell lines. Modified peptides will be isolated by a variation of the immunoaffinity technology we developed for phosphorylation profiling and will be identified by commonly practiced liquid chromatography-tandem mass spectrometry methods. To demonstrate that we can evaluate the relevance of the sites we find, we will collect and present information about known and novel human acetylated-lysine sites in an easy-to-use web-based format, as we have done for phosphorylation sites in PhosphoSite(r). This project has the potential to vastly increase the number of known acetylated-lysine sites and to greatly stimulate the newly emerging fields of lysine acetylation and acetylation biology. [unreadable] [unreadable] [unreadable] [unreadable] [unreadable]

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R43
  • Administering IC
    CA
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    151911
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    396
  • Ed Inst. Type
  • Funding ICs
    NCI:151911\
  • Funding Mechanism
  • Study Section
    ZCA1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    CELL SIGNALING TECHNOLOGY, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    DANVERS
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    01923
  • Organization District
    UNITED STATES